Credit Agricole Sa: Crédit Agricole Leasing & Factoring completes acquisition of German group Merca Leasing

BigBear.ai Holdings (BBAI) rose 5% to $2.41 after announcing over $225M in federal contract awards since July. The AI defense software company secured deals across homeland security, defense, and intelligence sectors. Despite the gain, shares are down 55% year-to-date. Palantir (PLTR) and Ambarella (AMBA) shares declined 0.6% and 0.9%, respectively.

Ventas (VTR) targets 15-17% NOI growth and expands its acquisition budget to $3 billion, according to Guinness Global Real Assets Fund's Q3 2026 investor letter. The healthcare REIT's stock has traded between $67.36 and $101.60 over the past 52 weeks, closing at $83.54 on October 12, 2026, with a market cap of $43.11 billion. The fund notes potential benefits from improving senior housing occupancy and limited new supply.

American Electric Power (AEP) secured up to $3.26 billion in federal funding to modernize the Texas grid, according to Guinness Global Real Assets Fund. The financing aims to improve grid reliability, lower electricity costs by $685 million over 30 years, and support job creation. AEP's stock traded between $112.54 and $140.58 over the past year, closing at $124.23 on October 12, 2026, with a market cap of $67.77 billion.

BigBear.AI (NYSE:BBAI) shares rose 5.22% to $2.42 on Tuesday. The company announced over $225 million in new government contracts since July, including deals with the FBI, U.S. Coast Guard, and NASA. CEO Kevin McAleenan attributed the growth to an expanding customer base and unique technology.

BioNTech's (BNTX) BNT113 vaccine failed to meet a key endpoint in a clinical trial, causing shares to slide. The company's P/S ratio is 7.09, above its historical median, but it remains unprofitable. Insiders have sold $89.8M in shares over the past year, and analysts are cautious about its oncology pipeline.

BioNTech's BNT113 failed to meet a primary endpoint in a phase 2/3 trial for head and neck cancer, causing its stock to drop ~6% in Tuesday trading. The AHEAD-MERIT study is ongoing. According to the company, the therapy did not achieve the required progression-free survival rate. Investors reacted negatively to the news, impacting the company's stock price.